PO.ET03.04 · 实验与分子治疗
通过他汀类药物再利用进行代谢重编程：逆转 Warburg 效应并克服胰腺导管腺癌吉西他滨耐药的策略
Metabolic reprogramming via statin repurposing: A strategy to reverse the Warburg effect and overcome gemcitabine resistance in pancreatic ductal adenocarcinoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景：胰腺导管腺癌（PDAC）仍是最致命的癌症之一，预计到 2030 年其死亡率将在癌症相关死亡中排名第二。吉西他滨是一线化疗药物，但常发生耐药，导致预后不良。代谢重编程，尤其是由缺氧和 HIF-1alpha 激活驱动的糖酵解增强，是吉西他滨耐药的关键机制。他汀类药物是常用的抑制 HMG-CoA 还原酶的降胆固醇药物，已显示出潜在的代谢和抗癌效应，且具有确立的安全性。本研究探讨了他汀类药物能否通过靶向糖酵解适应来克服 PDAC 中的吉西他滨耐药。
方法：用辛伐他汀单药或与吉西他滨联合处理吉西他滨耐药的 PDAC 细胞系（MIA PaCa-2 和 BxPC-3）及患者来源的 3D 类器官。结局指标包括细胞活力、凋亡、迁移、侵袭和糖酵解活性（通过细胞外酸化率 [ECAR] 和乳酸产生测定）。通过 RT-qPCR 和 Western blot 测定糖酵解相关基因 HIF-1alpha、HK2 和 LDHA 的表达。采用 HIF-1alpha 的药理学调节来验证机制。临床意义通过来自 50 名接受吉西他滨治疗的 PDAC 患者的 EUS-FNA 样本以及癌症基因组图谱（TCGA）的转录组数据进行评估。
结果：与亲本细胞系相比，辛伐他汀降低了吉西他滨耐药 PDAC 细胞的活力（IC50：20-21 μM 对亲本细胞的 37-39 μM；p <0.01），并与吉西他滨表现出协同作用（Bliss 评分：5.5 和 4.29），显著增强了抗肿瘤活性，分别使活力降低 41.7% 和 44.4%。联合处理显著抑制了迁移和侵袭并增加了凋亡（p <0.001），伴随裂解 PARP 和 caspase-3 的增加。耐药细胞表现出糖酵解升高，辛伐他汀（尤其与吉西他滨联合时）在 mRNA 和蛋白水平上均降低了乳酸、ECAR 以及 HIF-1alpha、HK2 和 LDHA 的表达（p <0.01），模拟了 HIF-1alpha 抑制。在两个 PDAC 类器官中，联合治疗破坏了结构并降低了活力，同时下调糖酵解基因。临床上，在我们接受吉西他滨治疗的队列和 TCGA 数据集中，高 HIF-1alpha/HK2/LDHA 表达与吉西他滨无应答及更差的 PFS/OS 相关。
结论：他汀类药物通过抑制 HIF-1alpha 驱动的糖酵解重编程恢复 PDAC 的吉西他滨敏感性，逆转了导致化疗耐药的代谢适应。凭借其确证的安全性、经济性和广泛可及性，他汀类药物提供了一种有前景、可即时转化的方法，以改善吉西他滨耐药 PDAC 的结局。
查看英文原文 English abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest cancers, with mortality projected to rank second in cancer-related deaths by 2030. Gemcitabine is a first-line chemotherapy, but resistance frequently develops, leading to poor prognosis. Metabolic reprogramming, particularly enhanced glycolysis driven by hypoxia and HIF-1alpha activation, is a key mechanism of gemcitabine resistance. Statins, commonly used cholesterol-lowering drugs that inhibit HMG-CoA reductase, have demonstrated potential metabolic and anti-cancer effects with an established safety profile. This study investigated whether statins could overcome gemcitabine resistance in PDAC by targeting glycolytic adaptation.
Methods: Gemcitabine-resistant PDAC cell lines (MIA PaCa-2 and BxPC-3) and patient-derived 3D organoids were treated with simvastatin alone or combined with gemcitabine. Outcomes included cell viability, apoptosis, migration, invasion, and glycolytic activity (measured by extracellular acidification rate [ECAR] and lactate production). Expression of glycolysis-related genes HIF-1alpha, HK2, and LDHA was measured by RT-qPCR and Western blotting. Pharmacological modulation of HIF-1alpha was used to validate the mechanism. Clinical significance was assessed via EUS-FNA samples from 50 patients with PDAC treated with Gemcitabine and transcriptomic data from The Cancer Genome Atlas (TCGA).
Results: Simvastatin reduced the viability of Gemcitabine-resistant PDAC cells compared with parental cell lines (IC50: 20-21 μM vs. 37-39 μM in parental cells; p <0.01) and showed synergy with Gemcitabine (Bliss scores: 5.5 and 4.29) and markedly enhanced anti-tumor activity, reducing viability by 41.7% and 44.4%, respectively. The combination significantly suppressed migration and invasion and increased apoptosis ( p <0.001), accompanied by increased cleaved PARP and caspase-3. Resistant cells exhibited elevated glycolysis, and simvastatin, especially in combination with Gemcitabine, reduced lactate, ECAR, and expression of HIF-1alpha, HK2, and LDHA at both mRNA and protein levels ( p <0.01), mimicking HIF-1alpha inhibition. In two PDAC organoids, combination therapy disrupted structure and reduced viability while downregulating glycolytic genes. Clinically, high HIF-1alpha/HK2/LDHA expression correlated with Gemcitabine nonresponse and worse PFS/OS in both our gemcitabine-treated cohort and TCGA dataset.
Conclusion: Statins restore gemcitabine sensitivity in PDAC by suppressing HIF-1alpha-driven glycolytic reprogramming, reversing the metabolic adaptations responsible for chemoresistance. With their proven safety, affordability, and wide availability, statins offer a promising, immediately translatable approach to improve outcomes in gemcitabine-resistant PDAC.
利益披露 Disclosure
T. Noma, None..
M. Shimada, None..
A. Goel, None.